CAR‐T‐OPENIA: Chimeric antigen receptor T‐cell therapy‐associated cytopenias. (21st November 2021)

• Record Type: Journal Article
• Authors: Taneja, Alankrita; Jain, Tania
• Other Names: Dholaria Bhagirathbhai R. guestEditor.; Sengsayadeth Salyka M. guestEditor.; Oluwole Olalekan O. guestEditor.; Savani Bipin N. guestEditor.
• Is Part Of: EJHaem. Volume 3(2022)Supplement 1
• Page Start: 32
• Page End: 38
• Publication Date: 2021-11-21
• Subjects: anemia -- chimeric antigen receptor -- neutropenia -- thrombocytopenia; Hematology -- Periodicals; 616.15
• DOI: 10.1002/jha2.350
• Languages: English
• ISSNs: 2688-6146

Abstract

Abstract: Chimeric antigen receptor (CAR) T‐cell is the most recent version in the evolution of cellular therapy with promising responses, which has revolutionized the management of some hematological malignancies in the current times. As the clinical use has progressed rather rapidly since the first approval in 2017, toxicities beyond cytokine release syndrome and immune effector cell‐associated neurological syndrome have surfaced. Cytopenias are common in <30 days ("early"), 30–90 days ("short‐term") as well as >90 days ("prolonged"); and have clinical implications to patient care as well as resource utilization. We review the details of etiology, factors associated with cytopenias, and management considerations for patients with cytopenias for each of these time‐frames. This would potentially serve as a clinical guide for hematological toxicity or CAR‐T‐OPENIA, which is commonly encountered with the use of CAR T‐cell therapy.